BuSpar Boosts Par, Watson, Mylan To First Quarter Gains In Anxious Market
Three generic drug manufacturers are back in favor on Wall Street following a successful court battle to win approval of generic versions of the anxiety drug BuSpar (buspirone).
You may also be interested in...
PhRMA's public image themes for 2001 will focus on an expanded definition of "access" to include both drug coverage and research incentives.
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011